OSE Pharma is a privately held clinical stage biopharmaceutical company with its corporate headquarters in Paris, France. In 2014, OSE Pharma acquired all assets related to a Phase III targeted Cancer Immune Therapy program from a multinational pharmaceutical company.
The Company is targeting cancer and pulmonary diseases and seeks to transform lives through the discovery, development, and manufacture of novel therapeutics that significantly improve treatment options for patients. OSE Pharma was founded by Dominique Costantini, M.D, and Emile Loria, M.D. Both are experienced professionals, with complementary expertise in successfully managing drug development and business operations in public companies in the US (Epimmune - Nasdaq) and in Europe (BioAlliance - Euronext).